The daily battle to do it all AND still get healthy meals and exercise into our routine can be tough, and this can wreak havoc on your health
That opens the door for Indian giants like Sun Pharmaceuticals, Dr Reddy's Laboratories , Zydus Lifesciences, Natco Pharma, and others to flood the market with generics priced around INR 3,0005,000 per month
GLP-1 receptor agonists were associated with markedly lower risks of major adverse cardiovascular events, progression of kidney disease, venous thromboembolism, and all-cause mortality compared to DPP-4 inhibitor therapy
Studies show Retatrutide users losing up to 24% of body weight compared to Tirzepatides 15-22% over similar periods
Two have regulatory histories worth knowing: BPI Labs received an FDA warning letter in March 2025, and Olympia Pharmaceuticals received an FDA Form 483 in May 2024